RT Journal Article
SR Electronic
T1 Pre-diagnostic circulating concentrations of insulin-like growth factor-1 and risk of COVID-19 mortality: results from UK Biobank
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.09.20149369
DO 10.1101/2020.07.09.20149369
A1 Fan, Xikang
A1 Yin, Cheng
A1 Wang, Jiayu
A1 Yang, Mingjia
A1 Ma, Hongxia
A1 Jin, Guangfu
A1 Song, Mingyang
A1 Hu, Zhibin
A1 Shen, Hongbing
A1 Hang, Dong
YR 2020
UL http://medrxiv.org/content/early/2020/07/11/2020.07.09.20149369.abstract
AB Background Coronavirus disease 2019 (COVID-19) deteriorates suddenly primarily due to excessive inflammatory injury, and insulin-like growth factor-1 (IGF-1) is implicated in endocrine control of the immune system. However, the effect of IGF-1 levels on COVID-19 prognosis remains unknown.Objective To investigate the association between circulating IGF-1 concentrations and mortality risk among COVID-19 patients.Design Prospective analysis.Setting UK Biobank.Participants 1425 COVID-19 patients who had pre-diagnostic serum IGF-1 measurements at baseline (2006-2010).Main outcome measures COVID-19 mortality (available death data updated to 22 May 2020). Unconditional logistic regression was performed to estimate the odds ratio (OR) and 95% confidence intervals (CIs) of mortality across the IGF-1 quartiles.Results Among 1425 COVID-19 patients, 365 deaths occurred due to COVID-19. Compared to the lowest quartile of IGF-1 concentrations, the highest quartile was associated with a 37% lower risk of mortality (OR: 0.63, 95% CI: 0.43-0.93, P-trend=0.03). The association was stronger in women and nonsmokers (both P-interaction=0.01).Conclusions Higher IGF-1 concentrations are associated with a lower risk of COVID-19 mortality. Further studies are required to determine whether and how targeting IGF-1 pathway might improve COVID-19 prognosis.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialUK Biobank received ethical approval from the NHS National Research Ethics Service North West (11/NW/0382; 16/NW/0274).Clinical Protocols https://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol.pdf Funding StatementThis study was funded by National Natural Science Foundation of China (81820108028, 81521004, and 81973127), National Key R&D Program of China (2016YFC1000200 and 2017YFC0908300), and Science Foundation for Excellent Young Scholars of Jiangsu (BK20190083). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank received ethical approval from the NHS National Research Ethics Service North West (11/NW/0382; 16/NW/0274). All participants provided written informed consent before enrolment in the study, which was conducted in accordance with the Declaration of Helsinki. The study protocol is available online (https://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol.pdf).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from UK Biobank (https://www.ukbiobank.ac.uk/), but restrictions apply to their availability. These data were used under licence for the current study and so are not publicly available. The data are available from the authors upon reasonable request and with permission of UK Biobank. http://biobank.ndph.ox.ac.uk/showcase/ COVID-19coronavirus disease 2019BMIbody mass indexMETmetabolic equivalentICDinternational classification of diseasesORodds ratioCIconfidence interval.